Covidien Loses a Major Motion. Hernia Mesh Litigation Enters a New Phase.

Publish Date : 06/05/2026

For years, thousands of patients alleged certain Covidien hernia mesh products Symbotex, Parietex, and related polyester-based meshes, caused serious complications ranging from chronic pain and adhesions to infections, bowel problems, recurrence, and the need for revision surgery. Today, more than 2,300 cases are pending in the federal multidistrict litigation before Judge Patti Saris in Massachusetts, with thousands more pending in state courts.

Recently, Covidien suffered an important setback.

In the bellwether case of Patterson v. Covidien, Judge Patti Saris denied Covidien’s motion for summary judgment, allowing the plaintiffs’ claims to proceed toward trial.

That ruling may prove to be one of the most significant developments in the litigation to date.

What Is Summary Judgment?

Summary judgment is often a defendant’s best opportunity to end a case before it ever reaches a jury.

In simple terms, the manufacturer asks the court to decide there are no factual disputes requiring a trial. If successful, the judge dismisses the claims and the jury never hears the case.

Covidien sought such a result, but the court refused.

Instead, Judge Saris concluded the disputes raised by the parties should be decided by jurors.

Means, the plaintiffs’ allegations survived one of the most significant legal hurdles in the case.

Why This Matters Beyond One Plaintiff

The Patterson case is not just another individual lawsuit.

It is the first bellwether trial in the Covidien MDL, essentially a test case intended to show how juries may react to evidence expected to be repeated across thousands of lawsuits.

Bellwether trials serve an important function. They allow both sides to assess strengths and weaknesses, and often provide information necessary to facilitate global settlement discussions.

Had Covidien prevailed on summary judgment, the momentum of the litigation could have changed dramatically. Instead, the opposite occurred and the case remains on track for trial. Meaning, a jury may soon hear evidence regarding the design, testing, warnings, and performance of Covidien’s hernia mesh products.

A Familiar Pattern in Medical Device Litigation

Medical device manufacturers frequently seek to avoid jury trials through motions like these.

Sometimes they succeed.

But when they do not, the stakes change because jurors, not lawyers and not judges, become the ultimate audience.

History has shown that once bellwether trials begin, litigation often enters a different phase. In the Bard hernia mesh litigation, for example, a series of verdicts and mounting pressure eventually helped produce settlements involving tens of thousands of cases.

No one can predict whether the Covidien litigation will follow the same path.

But the denial of summary judgment increases the pressure on the company considerably.

The Bigger Question

At the center of these cases is a straightforward issue:

Did Covidien adequately test, design, and warn about the risks associated with its polyester-based hernia mesh products?

Plaintiffs contend the answer is no.

Covidien, of course, disputes those allegations.

But after the recent ruling, that debate is one step closer to being resolved where many plaintiffs have long argued it belongs:

In front of a jury.

And after years of discovery, millions of pages of documents, and thousands of lawsuits, the Covidien hernia mesh litigation appears to be entering one of its most consequential chapters yet.